Motus gi announces first patient enrolled in a pilot study using the pure-vu® system for patients with lower gi bleeding being conducted by a leading u.s. medical center

Fort lauderdale, fla., march 15, 2021 (globe newswire) -- motus gi holdings, inc., (nasdaq: mots) ("motus gi" or the "company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today the enrollment of the first patient in a pilot study of the pure-vu® system. the study is evaluating the clinical and economic outcomes using the pure-vu system in patients with emergent lower gastrointestinal bleeding that are evaluated and treated in the intensive care unit (icu) or the rapid inpatient endoscopy suite.
MOTS Ratings Summary
MOTS Quant Ranking